Medtronic Expands Surgical Business - Analyst Blog
July 08 2011 - 1:05PM
Zacks
Leading medical devices player Medtronic (MDT)
has taken the inorganic route to strengthen its presence in
advanced surgical devices. The company recently decided to acquire
two companies – Salient Surgical Technologies for $525 million and
Peak Surgical for $120 million. Both the transactions are subject
to several approvals.
Salient Surgical deals with haemostatic sealing of soft tissue
and bone in a variety of surgical procedures
including orthopedic surgery, spine, open abdominal and
thoracic procedures. Following this deal, Medtronic’s Surgical
Technologies portfolio would include Aquamantys system with
Transcollation technology. Salient records annualized revenue of
about $100 million. Medtronic already holds an ownership stake in
Salient, excluding which the transaction value would be
approximately $480 million.
Peak Surgical specializes in surgical instruments based on its
PlasmaBlade technology. The Peak PlasmaBlade consists of disposable
cutting devices with insulation technology that provides accuracy
of scalpel and bleeding control with minimal thermal tissue damage.
The technology is approved for several applications – Ear, Nose and
Throat (ENT), plastic reconstructive, orthopaedic and general
surgery.
Peak Surgical’s annualized revenue is $20 million. After taking
into account Medtronic’s current stake in Peak Surgical, the
transaction value comes to approximately $105 million.
During the last reported quarter, revenues from Surgical
Technologies segment increased 9% to $298 million (7% at CER)
driven by strong performances across the portfolio of ENT, power
systems and navigation product lines, as well as balanced growth
across capital equipment, disposables and service.
Medtronic has been looking at diversifying its portfolio over
the past few quarters as its core segments – Cardiac Rhythm Disease
Management (CRDM) and Spinal have been witnessing several
challenges and lower revenues. However, the two recent acquisitions
are unlikely to have any significant impact on the top line in near
future as Surgical Technologies account for 7% of total sales. The
company also faces tough competition from players such as
Boston Scientific Corporation (BSX) and St
Jude Medical (STJ).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024